Genocea Biosciences, Inc. (GNCA)
Price:
0.00 USD
( - -0.00 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Genmab A/S
VALUE SCORE:
11
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
NEWS
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
investorplace.com
2022-05-25 10:38:35Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares. The post Genocea Biosciences Is Shutting Down.
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
pennystocks.com
2022-04-11 09:36:14What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
benzinga.com
2022-04-08 14:35:03Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the.
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
globenewswire.com
2022-03-14 17:06:00CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET.
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-10 10:25:27Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
globenewswire.com
2022-03-08 17:39:00Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
globenewswire.com
2022-03-03 08:00:00CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10t h at 8:30 a.m. E.T.
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
globenewswire.com
2022-02-10 19:50:00CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET.
Genocea to Present at Upcoming Investor Conferences
globenewswire.com
2022-01-05 17:46:00CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
globenewswire.com
2021-11-10 19:26:00CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17th at 1:20 PM ET.
Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-10-28 13:29:03Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript
Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast
globenewswire.com
2021-10-21 16:30:00CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28t h at 8:30 a.m. E.T.
Genocea to Present at Upcoming Conferences
globenewswire.com
2021-09-28 16:30:00CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October.
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
globenewswire.com
2021-09-13 16:52:00CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors.
Genocea to Present at Upcoming Scientific and Investor Conferences
globenewswire.com
2021-09-07 19:40:00CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.
Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?
zacks.com
2021-08-23 09:56:15Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
No data to display
Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.
investorplace.com
2022-05-25 10:38:35Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares. The post Genocea Biosciences Is Shutting Down.
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
pennystocks.com
2022-04-11 09:36:14What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients
benzinga.com
2022-04-08 14:35:03Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the.
Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference
globenewswire.com
2022-03-14 17:06:00CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET.
Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-10 10:25:27Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript
Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting
globenewswire.com
2022-03-08 17:39:00Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors
Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast
globenewswire.com
2022-03-03 08:00:00CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, March 10t h at 8:30 a.m. E.T.
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference
globenewswire.com
2022-02-10 19:50:00CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17th at 10:40 A.M. ET.
Genocea to Present at Upcoming Investor Conferences
globenewswire.com
2022-01-05 17:46:00CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
globenewswire.com
2021-11-10 19:26:00CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17th at 1:20 PM ET.
Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-10-28 13:29:03Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript
Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast
globenewswire.com
2021-10-21 16:30:00CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2021 corporate update conference call and live audio webcast on Thursday, October 28t h at 8:30 a.m. E.T.
Genocea to Present at Upcoming Conferences
globenewswire.com
2021-09-28 16:30:00CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October.
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
globenewswire.com
2021-09-13 16:52:00CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors.
Genocea to Present at Upcoming Scientific and Investor Conferences
globenewswire.com
2021-09-07 19:40:00CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September.
Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?
zacks.com
2021-08-23 09:56:15Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.